Results 41 to 50 of about 43,211 (293)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes

Substance Abuse: Research and Treatment, 2013
Given that buprenorphine + naloxone is prescribed for opioid-dependent pregnant women, it is important to examine the extent to which it differs from buprenorphine alone, methadone, or methadone-assisted withdrawal on neonatal and maternal outcomes ...
Ingunn O. Lund, Gabriele Fischer, Gabrielle K. Welle-Strand, Kevin E. O'grady, Kimber Debelak, William R. Morrone, Hendrέe E. Jones   +6 more
doaj   +1 more source

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach

Addiction Science & Clinical Practice, 2020
Background The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk ...
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo, S. Elise Durante, Skye P. Barbic, Daniel Lin, Steve Mathias, Pouya Azar   +7 more
doaj   +1 more source

3D Bioprinting of Thick Adipose Tissues with Integrated Vascular Hierarchies

Advanced Functional Materials, Volume 35, Issue 12, March 18, 2025.
An advanced 3D bioprinting technique is used here to create thick adipose tissues with a central, vessel and extensive branching. The construct is made using alginate, gelatin and collagen‐based bioinks. Flow through the complex vessel network is demonstrated as well as its successful integration with a femoral artery following implantation in a rat ...
Idit Goldfracht, Majd Machour, Inbal Michael, Maria Bulatova, Janette Zavin, Shulamit Levenberg   +5 more
wiley   +1 more source

Low-dose buprenorphine initiation during pregnancy: a case report

AJOG Global Reports
Buprenorphine is recommended for pregnant patients with opioid use disorder. Traditional buprenorphine initiation requires moderate withdrawal symptoms to prevent precipitating withdrawal.
Shivania Reddy, BSc, Caitlin E. Martin, MD, MPH, FACOG, FASAM   +1 more
doaj   +1 more source

Synergistic Osteogenesis After Co‐Administration of cmRNAs Encoding BMP‐2 and BMP‐7 Utilizing a Transcript‐Activated Matrix

Advanced Functional Materials, EarlyView.
This study demonstrates that the dual delivery of BMP‐2/‐7 coding cmRNAs for bone healing is demonstrated as feasible, safe, and highly osteogenic. Compared to single BMP‐2 or BMP‐7 cmRNAs, the combination enhances the production of both mineral and organic components of the extracellular matrix when delivered using a collagen‐HA scaffold, supporting ...
Claudia Del Toro Runzer, Joanna M. Sadowska, Nadia Roumans, Christian Plank, Christopher H. Evans, Fergal J. O'Brien, Martijn van Griensven, Elizabeth R. Balmayor   +7 more
wiley   +1 more source

Barriers To Recovery For Bangor\u27s Buprenorphine Patients [PDF]

, 2015
There are several buprenorphine providers at EMMc\u27s Center for Family Medicine serving the greater Bangor, ME region - an area of substantial opiate use.
Keller, Erin, McLaren, John R
core   +1 more source

Ethanol reversal of tolerance to the respiratory depressant effects of morphine [PDF]

, 2015
Opioids are the most common drugs associated with unintentional drug overdose. Death results from respiratory depression. Prolonged use of opioids results in the development of tolerance but the degree of tolerance is thought to vary between different ...
A Fugelstad, A Fugelstad, Abi Lyndon, AJ Ruttenber, Anne Lingford-Hughes, AR Lingford-Hughes, B Levine, BM Mathers, CA Paronis, Chris Bailey, CK Kuo, CN Lessov, CP Bailey, CP Bailey, CP Bailey, E Kelly, E Valjent, Eamonn Kelly, EB Rex, EJ Waite, F Chen, FL Smith, FL Smith, Graeme Henderson, GS Ling, H Sakakibara, HW Matthes, HY Lin, I Rodriguez-Martin, J Llorente, J McPherson, J Reneau, JM White, Joanne Roberts, John MacLachlan, JT Williams, JW Lewis, KL McGilliard, L He, LC Hull, LC Saland, LJ Sim-Selley, LM Bohn, LQ Hong-Brown, M Aliczki, M Hickman, M Hickman, M Inoue, M Pierce, Matthew Hickman, N Quillinan, NG Shah, R Cornish, R Romberg, Rob Hill, S Darke, S Darke, S Kishioka, Sarah Withey, SJ Slater, SV Dighe, TC Green, Yvonne Kershaw   +62 more
core   +3 more sources

A Case Study of Pain Management at End-of-Life for a Patient on High-Dose Buprenorphine

Journal of Patient Experience, 2022
In Australia, high-dose sublingual buprenorphine and long-acting injectable buprenorphine are available. High-dose buprenorphine is used predominantly in the setting of opioid use disorder and has a role in chronic pain.
Naomi T Katz, Martyn Lloyd-Jones, Lucy Demediuk, Kerry McLaughlin, Megan McKechnie, Michelle Gold   +5 more
doaj   +1 more source

Biologically Active Implants Prevent Mortality in a Mouse Sepsis Model

Advanced Healthcare Materials, EarlyView.
A modular, triple‐action titanium implant is developed to prevent implant‐associated infections by repelling bacteria, killing pathogens, and enhancing tissue integration. Coatings with phage cocktails targeting P. aeruginosa and S. aureus show significant bacterial reduction and improved survival in a mouse sepsis model.
Martin Stark, Fereshteh Bayat, Sara Rahmani, Mathura Thirugnanasampanthar, Taylor Kramer, Elise Schwarz, David Wilson, Jeffrey I. Weitz, Zeinab Hosseinidoust, Tohid F. Didar   +9 more
wiley   +1 more source

Buprenorphine in Neonatal Abstinence Syndrome. [PDF]

, 2018
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and ...
Kraft, Walter K.
core   +1 more source